HUBEI HONGYUAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Stock
Equities
301246
CNE100005ZB9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.9 CNY | -1.55% |
|
-4.33% | -38.80% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 2.06B 285M | Sales 2023 | 2.05B 284M | Capitalization | 10.39B 1.44B |
|---|---|---|---|---|---|
| Net income 2022 | 435M 60.08M | Net income 2023 | 87M 12.02M | EV / Sales 2022 * | - |
| Net cash position 2022 | 51.05M 7.05M | Net cash position 2023 | 1.83B 253M | EV / Sales 2023 | 4.17 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
116
x | Employees | 2,075 |
| Yield 2022 * |
-
| Yield 2023 |
0.19% | Free-Float | 37.32% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.55% | ||
| 1 week | -4.33% | ||
| Current month | -2.45% | ||
| 1 month | +8.31% | ||
| 3 months | -24.93% | ||
| 6 months | -43.56% | ||
| Current year | -38.80% |
1 week
15.80
16.32
1 month
14.7118.90
Current year
14.1626.30
1 year
14.1637.74
3 years
14.1645.00
5 years
14.1645.00
10 years
14.1645.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shuang Xi Xu
CEO | Chief Executive Officer | 58 | - |
Gao Liang Lei
CHM | Chairman | 59 | - |
Ke Feng Zeng
DFI | Director of Finance/CFO | 39 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qing Xie
BRD | Director/Board Member | 61 | - |
Si Yuan Cheng
BRD | Director/Board Member | 51 | - |
Zhi Hua Deng
BRD | Director/Board Member | 54 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 15.9 | -1.55% | 4,614,353 |
| 24-05-20 | 16.15 | -0.31% | 3,762,403 |
| 24-05-17 | 16.2 | +0.56% | 4,448,275 |
| 24-05-16 | 16.11 | 0.00% | 4,902,400 |
| 24-05-15 | 16.11 | -3.07% | 7,085,439 |
End-of-day quote Shenzhen S.E., May 20, 2024
More quotes
Hubei Hongyuan Pharmaceutical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of organic chemical raw materials, pharmaceutical intermediates, raw materials and pharmaceutical preparations. The Company is also engaged in the production of lithium hexafluorophosphate, one of the main materials for lithium battery electrolyte. The Company's main products are divided into organic chemical raw materials such as glyoxal in the ethylene glycol reaction chain, pharmaceutical intermediates such as glyoxylic acid, 2-methyl-5-nitroimidazole and other products, and raw materials such as metronidazole; Pharmaceutical intermediates guanine, diacetylguanine and other products in the reaction chain of methyl cyanoacetate and guanidine hydrochloride. The Company distributes its products in the domestic market and overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -38.80% | 879M | |
| +37.08% | 723B | |
| +31.16% | 598B | |
| -3.39% | 364B | |
| +19.99% | 331B | |
| +3.84% | 288B | |
| +15.91% | 244B | |
| +9.83% | 210B | |
| -5.07% | 208B | |
| +8.71% | 169B |
- Stock Market
- Equities
- 301246 Stock